Application Serial No. 09/765,151 Amendment dated November 12, 2003 Reply to Office Action dat d September 12, 2003

Claims:

1. (Currently Amended) A method of monitoring the compliance of a patient in following a medication regimen, said method comprising the steps of:

providing in combination an orally administrable composition, which is part of a medication regimen, and at least one marker, said at least one marker being present in said combination in a form and sufficient amount to cause a contact staining coloration of at least a portion of a mucous membrane or buccal membrane of the oral and/or pharyngeal cavity of a patient following oral ingestion of said combination by said patient;



visually observing the oral and/or pharyngeal cavity of said patient; and determining the presence or absence of said contact staining coloration for determining whether said patient has ingested said combination in compliance with the medication regimen.

- 2. (Original) The method of claim 1 wherein said composition is a medication composition.
- 3. (Original) The method of claim 1 wherein said composition is a placebo composition.

Application Serial No. 09/765,151 Amendment dated November 12, 2003 Reply to Office Action dated September 12, 2003

4. (Currently Amended) The method of claim 1 wherein visually observing the oral and/or pharyngeal cavity of said patient to determine the presence or absence of contact staining coloration further comprises the step of directing natural light into the oral and/or pharyngeal cavity of said patient prior to observing the oral and/or pharyngeal cavity of said patient in order to directly observe said contact staining coloration.



- 5. (Currently Amended) The method of claim 1 wherein visually observing the oral and/or pharyngeal cavity of said patient to determine the presence or absence of contact staining coloration further comprises the step of directing an optimal exciting light into the oral and/or pharyngeal cavity of said patient prior to observing the oral and/or pharyngeal cavity of said patient in order to observe said contact staining coloration through fluorescence.
- 6. ___(Original) The-method-of-claim 5 wherein said-optimal-exciting light is a violet-blue to blue light having a wavelength in a range of from about 430 nm to about 490 nm.

Application Serial No. 09/765,151

Amendment dated November 12, 2003

Reply to Office Action dated Septemb r 12, 2003

- 7. (Original) The method of claim 1 wherein visually observing said oral and/or pharyngeal cavity comprises visually observing a mucous membrane in said oral and/or pharyngeal cavity.
- 8. (Original) The method of claim 1 wherein said marker is carmine red dye.
- 9. (Original) The method of claim 1 wherein said marker is selected from the group consisting of indigo carmine, methylene blue, tartrazine, laccaic acid, beta-carotene, FD&C blue 1, FD&C blue 2, FD&C green 3, FD&C red 3, FD&C red 40, FD&C yellow 6, and riboflavin.
- 10. (Currently Amended) The method of claim 1 further comprising providing multiple markers in said combination, one of said markers causing a contact staining coloration of portion of the oral and/or pharyngeal cavity for a longer time than another of the markers, and determining the presence or absence of contact staining colorations caused by the multiple markers to determine a time frame in which the combination was ingested.



Application Serial No. 09/765,151 Amendment dated Novemb r 12, 2003 Reply to Office Action dated September 12, 2003

- 11. (Currently Amended) The method of claim 10 wherein one of said multiple markers causes a different contact staining coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.
- 12. (Currently Amended) The method of claim 1 further comprising providing multiple markers in said combination wherein one of said multiple markers causes a different contact staining coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.
- 13. (Currently Amended) The method of claim 1 further comprising providing multiple markers in said combination, one of said markers causing a contact staining coloration of a portion of the oral and/or pharyngeal cavity detectable with natural light and another of said markers causing contact staining coloration detectable with a light which causes fluorescence.
- 14. (Currently-Amended) The method of claim 1 further comprising providing multiple markers in said combination, the markers being detectable with a light which causes fluorescence, one of said markers causing a different fluorescent contact staining coloration of a portion of the oral and/or pharyngeal cavity than the fluorescent contact staining coloration caused by the other marker.



Application Serial No. 09/765,151 Amendment dated November 12, 2003 Reply to Office Action dated September 12, 2003

15. (Currently Amended) In combination:an orally administrable composition; and

at least one marker, said marker being present in said combination in a sufficient amount and form to cause a contact staining coloration of at least a portion of a mucous membrane or buccal membrane of the oral and/or pharyngeal cavity of a patient following ingestion of said combination by said subject;

said contact staining coloration of the oral and/or pharyngeal cavity being visually observable for determining whether said patient has ingested said combination in compliance with a medication regimen.

- 16. (Original) The combination of claim 15 wherein said at least one marker is applied to the outer surface of said composition.
- 17. (Original) The combination of claim 15 wherein said at least one marker is interspersed throughout said composition.
- 18. (Original) The combination of claim 15 wherein the form of said composition is selected from the group consisting of a chewable tablet, a pill, a capsule, and a liquid.



Application Serial No. 09/765,151 Amendment dated November 12, 2003 Reply to Offic Action dated September 12, 2003

- 19. (Currently Amended) The combination of claim 15 wherein said marker is operable to cause contact staining coloration of a mucous membrane of said oral and/or pharyngeal cavity.
- 20. (Original) The combination of claim 15 wherein the half-life of said at least one marker in the human system is comparable to the half-life of said composition in the human system.
- 21. (Original) The combination of claim 15 wherein said at least one marker is carmine red dye.
- 22. (Original) The combination of claim 15 wherein said at least one marker is selected from the group consisting of indigo carmine, methylene blue, tartrazine, laccaic acid, beta-carotene, FD&C blue 1, FD&C blue 2, FD&C green 3, FD&C red 3, FD&C red 40, FD&C yellow 6, and riboflavin.
- 23. (Original) The combination of claim 15 further comprising multiple markers in said combination.

Application Serial No. 09/765,151 Amendment dated November 12, 2003 Reply to Office Action dated September 12, 2003

- 24. (Currently Amended) The combination of claim 23 wherein one of said multiple markers causes a contact staining coloration of portion of the oral and/or pharyngeal cavity for a longer time than another of the markers so that the presence or absence of contact staining colorations caused by the multiple markers may be visually observed to determine a time frame in which the combination was ingested.
- 25. (Currently Amended) The combination of claim 23 wherein one of said multiple markers causes a different contact staining coloration in the portion of the oral and/or pharyngeal cavity than another of said markers.
- 26. (Currently Amended) The combination of claim 23 wherein one of said multiple markers causes a contact staining coloration of a portion of the oral and/or pharyngeal cavity detectable with natural light and another of said markers causes contact staining coloration detectable with a light which causes fluorescence.
- 27. (Currently Amended) -The combination of claim 23 wherein the multiple markers are detectable with a light which causes fluorescence, one of said markers causing a different fluorescent contact staining coloration of a portion of the oral and/or pharyngeal cavity than the fluorescent contact staining coloration caused by the other marker.

